Plasminogen Activator Inhibitor-type 1 in Lewis Lung Carcinoma

Overview

Journal Histochemistry

Specialty Biochemistry

Date 1990 Jan 1

PMID 2109745

Citations 12

Authors

P Kristensen

C Pyke

L R Lund

P A Andreasen

K Dano

Affiliations

Soon will be listed here.

Abstract

Plasminogen activator inhibitor-type 1 (PAI-1) was identified in extracts of Lewis lung carcinoma, and its immunohistochemical localization was studied together with that of urokinase-type (u-PA) and tissue-type (t-PA) plasminogen activators. All primary tumors (n = 11) contained heterogeneously distributed immunoreactivity against each of the three components. Most often, areas that contained u-PA immunoreactivity also contained PAI-1 immunoreactivity. However, several areas showed a strong u-PA immunoreactivity, but no or low PAI-1 immunoreactivity. The latter staining pattern was only found in peripheral areas, and usually in areas with histological signs of tissue destruction. Lung metastases always contained u-PA immunoreactivity, while PAI-1 immunoreactivity was found in most, but not all, metastases. t-PA immunoreactivity was found in a few scattered tumor cells, in primary carcinomas as well as metastases. Controls that included absorption with highly purified antigen preparations and immunoblotting, indicated that all the immunoreactivity represented genuine PAI-1, u-PA and t-PA, respectively. The results are consistent with an assumption that the plasminogen activation system, and particularly u-PA and PAI-1, plays a role in regulation of breakdown of extracellular matrix proteins during invasive growth in this carcinoma.

Citing Articles

Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.

Plebani M, Herszenyi L, Carraro P, De Paoli M, Roveroni G, Cardin R Clin Exp Metastasis. 1997; 15(4):418-25.

PMID: 9219730 DOI: 10.1023/a:1018454305889.

Laminin and collagen IV subunit distribution in normal and neoplastic tissues of colorectum and breast.

Hewitt R, Powe D, Morrell K, Balley E, Leach I, Ellis I Br J Cancer. 1997; 75(2):221-9.

PMID: 9010030 PMC: 2063263. DOI: 10.1038/bjc.1997.37.

Up-regulation of urokinase-type plasminogen activator in squamous cell carcinoma of human larynx.

Parolini S, Flagiello D, Cinquetti A, Gozzi R, Cristini S, Cappiello J Br J Cancer. 1996; 74(8):1168-74.

PMID: 8883400 PMC: 2075918. DOI: 10.1038/bjc.1996.512.

Prognostic relevance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in gastric cancer.

Ito H, Yonemura Y, Fujita H, Tsuchihara K, Kawamura T, Nojima N Virchows Arch. 1996; 427(5):487-96.

PMID: 8624578 DOI: 10.1007/BF00199509.

Activities, localizations, and roles of serine proteases and their inhibitors in human brain tumor progression.

Yamamoto M, Sawaya R, Mohanam S, Rao V, Bruner J, Nicolson G J Neurooncol. 1994; 22(2):139-51.

PMID: 7745466 DOI: 10.1007/BF01052889.

References

Larsson L, Skriver L, Nielsen L, Kristensen P, Dano K . Distribution of urokinase-type plasminogen activator immunoreactivity in the mouse. J Cell Biol. 1984; 98(3):894-903. PMC: 2113128. DOI: 10.1083/jcb.98.3.894. View

McGadey J . A tetrazolium method for non-specific alkaline phosphatase. Histochemie. 1970; 23(2):180-4. DOI: 10.1007/BF00305851. View

Laemmli U . Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970; 227(5259):680-5. DOI: 10.1038/227680a0. View

Stephens R, Pollanen J, Tapiovaara H, Leung K, Sim P, Salonen E . Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol. 1989; 108(5):1987-95. PMC: 2115548. DOI: 10.1083/jcb.108.5.1987. View

Kristensen P, Nielsen L, Andresen P, Larsson L, Dano K . Immunocytochemical demonstration of tissue-type plasminogen activator in endocrine cells of the rat pituitary gland. J Cell Biol. 1985; 101(1):305-11. PMC: 2113636. DOI: 10.1083/jcb.101.1.305. View

Pannekoek H, Veerman H, Lambers H, Diergaarde P, Verweij C, van Zonneveld A . Endothelial plasminogen activator inhibitor (PAI): a new member of the Serpin gene family. EMBO J. 1986; 5(10):2539-44. PMC: 1167150. DOI: 10.1002/j.1460-2075.1986.tb04532.x. View

Pollanen J, Hedman K, Nielsen L, Dano K, Vaheri A . Ultrastructural localization of plasma membrane-associated urokinase-type plasminogen activator at focal contacts. J Cell Biol. 1988; 106(1):87-95. PMC: 2114947. DOI: 10.1083/jcb.106.1.87. View

Kristensen P, Larsson L, Nielsen L, Andreasen P, Dano K . Human endothelial cells contain one type of plasminogen activator. FEBS Lett. 1984; 168(1):33-7. DOI: 10.1016/0014-5793(84)80201-x. View

Granelli-Piperno A, Reich E . A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med. 1978; 148(1):223-34. PMC: 2184915. DOI: 10.1084/jem.148.1.223. View

10.

Vuento M, Vaheri A . Purification of fibronectin from human plasma by affinity chromatography under non-denaturing conditions. Biochem J. 1979; 183(2):331-7. PMC: 1161563. DOI: 10.1042/bj1830331. View

11.

OSSOWSKI L, Reich E . Changes in malignant phenotype of a human carcinoma conditioned by growth environment. Cell. 1983; 33(2):323-33. DOI: 10.1016/0092-8674(83)90414-2. View

12.

Andreasen P, Christensen T, Huang J, Nielsen L, Wilson E, Dano K . Hormonal regulation of extracellular plasminogen activators and Mr approximately 54,000 plasminogen activator inhibitor in human neoplastic cell lines, studied with monoclonal antibodies. Mol Cell Endocrinol. 1986; 45(2-3):137-47. DOI: 10.1016/0303-7207(86)90141-3. View

13.

Erickson L, Lawrence D, Loskutoff D . Reverse fibrin autography: a method to detect and partially characterize protease inhibitors after sodium dodecyl sulfate--polyacrylamide gel electrophoresis. Anal Biochem. 1984; 137(2):454-63. DOI: 10.1016/0003-2697(84)90113-1. View

14.

Kristensen P, Hougaard D, Nielsen L, Dano K . Tissue-type plasminogen activator in rat adrenal medulla. Histochemistry. 1986; 85(5):431-6. DOI: 10.1007/BF00982674. View

15.

Riccio A, Lund L, Sartorio R, Lania A, Andreasen P, Dano K . The regulatory region of the human plasminogen activator inhibitor type-1 (PAI-1) gene. Nucleic Acids Res. 1988; 16(7):2805-24. PMC: 336434. DOI: 10.1093/nar/16.7.2805. View

16.

Vassalli J, Baccino D, Belin D . A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol. 1985; 100(1):86-92. PMC: 2113459. DOI: 10.1083/jcb.100.1.86. View

17.

Erickson L, Hekman C, Loskutoff D . The primary plasminogen-activator inhibitors in endothelial cells, platelets, serum, and plasma are immunologically related. Proc Natl Acad Sci U S A. 1985; 82(24):8710-4. PMC: 391506. DOI: 10.1073/pnas.82.24.8710. View

18.

Saksela O, Rifkin D . Cell-associated plasminogen activation: regulation and physiological functions. Annu Rev Cell Biol. 1988; 4:93-126. DOI: 10.1146/annurev.cb.04.110188.000521. View

19.

Nielsen L, Andreasen P, Skriver L, Dano K . Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular mass. FEBS Lett. 1986; 196(2):269-73. DOI: 10.1016/0014-5793(86)80261-7. View

20.

Philips M, Juul A, Thorsen S, Selmer J, Zeuthen J . Immunological relationship between the fast-acting plasminogen activator inhibitors from plasma, blood platelets and endothelial cells demonstrated with a monoclonal antibody against an inhibitor from placenta. Thromb Haemost. 1986; 55(2):213-7. View